BillionToOne
BillionToOne is a precision diagnostics company. Its molecular counting platform enables accurate DNA quantification for prenatal and oncology testing.
Secondary Market Price
How BillionToOne Measures Up
To help you manage your BillionToOne equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of BillionToOne's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future BillionToOne Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for BillionToOne's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
BillionToOne is a precision diagnostics company that develops molecular diagnostics to improve accuracy and accessibility. The company utilizes a proprietary molecular counting platform to quantify DNA molecules at the single-count level, enhancing disease detection. This technology is applied to prenatal and oncology testing through products such as UNITY Complete®, Northstar Select®, and Northstar Response®, which screen for conditions including cystic fibrosis and spinal muscular atrophy. BillionToOne was founded in 2016 by Oguzhan Atay and David Tsao and is headquartered in Menlo Park, California.
The company became publicly traded in 2025 and has shown substantial financial growth, reporting a 117% revenue increase in the third quarter of 2025 compared to the same period in 2024. For 2026, BillionToOne has projected revenue between $415 million and $430 million. A recent collaboration will integrate the company’s prenatal and oncology tests into Epic’s Aura diagnostics suite to streamline clinical workflows. In late 2025, Anthony Pagano also joined the Board of Directors to serve as the Audit Committee Chair.
- Premji Invest
- Neuberger Berman
- Adams Street Partners
- Baillie Gifford
- Hummingbird Ventures
- Civilization Ventures
- Libertus Capital
- Fifty Years
- NeoTribe Ventures
- Norwest Venture Partners
- Four Rivers Group
- Y Combinator
- Co-Founder, Oguzhan Atay
- Co-Founder, David Tsao
- Co-Founder, Sukrit Silas
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is BillionToOne worth joining?
Evaluating an offer from a private company like BillionToOne requires assessing the potential value of its equity alongside salary and benefits. A platform like Prospect can help by providing data-driven projections and comparative analysis to determine if you could be making more somewhere else.
What should I do with my BillionToOne stock?
The best course of action for your private stock depends on your personal financial situation, goals, and risk tolerance. Using a tool like Prospect Equity can help you build a customized, multi-year strategy for exercising options and selling shares to maximize your potential returns.
Can you sell BillionToOne stock?
As a private company, BillionToOne stock is generally illiquid, but opportunities to sell may arise through company-approved tender offers or secondary market sales. Tender offer tools can help you decide how much to sell and which shares are most tax-optimal for your situation.
How can I find the value of my BillionToOne stock?
Valuing private stock is complex, but it's often based on the company's last 409A valuation and any available secondary market prices. Platforms like Prospect use machine learning models and proprietary data to help you forecast the future value of your shares.
What is BillionToOne's equity worth?
The precise worth of private equity fluctuates and is difficult to determine until a liquidity event like an IPO or acquisition. You can get a better understanding of its potential value by using predictive models that project a likely range of outcomes based on various data points.
What is BillionToOne's stock ticker symbol?
As a private, pre-IPO company, BillionToOne does not have a stock ticker symbol because its shares are not traded on a public stock exchange. Ticker symbols are assigned only when a company completes its initial public offering (IPO).
Can I buy or sell BillionToOne stock?
As an employee, you can "buy" stock by exercising your vested options, while selling is typically limited to specific events like tender offers. Customized strategies can help you determine the optimal time to exercise and sell to minimize taxes and maximize value.
What is the criteria to buy or invest in BillionToOne stock?
Investing in a private company like BillionToOne is typically restricted to institutional or accredited investors and employees who receive equity as compensation. If you are an employee, platforms like Prospect are designed to help you manage that equity but do not facilitate direct investment for the general public.
